

patients with the Zollinger–Ellison syndrome, though it was reported to be effective by itself in a single patient¹⁰ and in combination with fluorouracil in one series of patients.¹¹

In 1976 two reports^{1,2} were published on the successful use of streptozotocin in the treatment of malignant gastrinoma by direct intra-arterial injection through the celiac axis: prolonged clinical remissions and marked reductions in size and number of metastases occurred. Significant side effects were few and consisted of nausea, vomiting, mild hypoglycemia and a mild transient increase in the levels of serum transaminases. No significant nephrotoxic effects were encountered.

In this paper we have described another case in which remission of

metastatic malignant gastrinoma was induced by the intra-arterial use of streptozotocin. A decline in the serum gastrin level to normal was associated with a clinical remission that lasted more than 2 years, and a rise in the gastrin level preceded clinical deterioration by more than 6 months. Therefore, serial determination of this level can be useful in predicting the course of malignant gastrinoma and thus in planning its management.

References

1. HAYES JR, O'CONNELL N, O'NEILL T, FENNELLY JJ, WEIR DG: Successful treatment of a malignant gastrinoma with streptozotocin. *Gut* 1976; 17: 285–288
2. STADIL F, STAGE G, REHFELD JF, EFSER F, FISCHERMAN K: Treatment of Zollinger–Ellison syndrome with streptozotocin. *N Engl J Med* 1976; 294: 1440–1442
3. CRYER PE, KISNER JN (eds): Clinicopathologic conference: metastatic pancreatic islet

cell carcinoma with peptic ulcer disease and hypercalcemia. *Am J Med* 1977; 63: 142–151

4. ELLISON EH, WILSON SD: The Zollinger–Ellison syndrome updated. *Surg Clin North Am* 1967; 47: 1115–1124
5. Idem: The Zollinger–Ellison syndrome: reappraisal and evaluation of 260 registered cases. *Ann Surg* 1964; 160: 512–523
6. MCCARTHY DM: Report on the United States experience with cimetidine in Zollinger–Ellison syndrome. *Gastroenterology* 1978; 74: 453–458
7. BRODER LE, CARTER SK: Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. *Ann Intern Med* 1973; 79: 108–118
8. MURRAY-LYON IM, EDDLESTON ALWF, WILLIAMS R, BROWN M, HOGGIN BM, BENNETT A, EDWARDS JC, TAYLOR KW: Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. *Lancet* 1968; 2: 895–898
9. PASSARO E JR, GORDON HE: Malignant gastrinoma following total gastrectomy. *Arch Surg* 1974; 108: 444–448
10. SACOFF L, FRANKLIN D: Streptozotocin in the Zollinger–Ellison syndrome. *Lancet* 1975; 2: 504–505
11. MOERTEL CG, HANLEY JA, JOHNSON LA: Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. *N Engl J Med* 1980; 303: 1189–1194

Resolution of massive renal artery thromboembolism with conservative therapy

RAYMONDE F. GAGNON,* MD, FRCP[C]

KARIN STRAATON,* MD

MILTON J. HERBA,† MD, FRCP[C]

MICHAEL KAYE,* MB, FRCP[C]

The clinical diagnosis of renal artery thromboembolism remains difficult in spite of the availability of new radioisotope techniques and improved angiographic procedures. Furthermore, firm therapeutic guidelines for established cases, even when the thromboembolism is massive, are lacking. There is, however, increasing documentation for the efficacy of various forms of nonsurgical treatment, including systemic administration of anticoagulants,¹ direct intra-arterial infusion of heparin,² papaverine² or

fibrinolytic agents,³ transcatheter thromboembolectomy⁴ and supportive care only.⁵

In this report we describe a patient with angiographically proven complete occlusion of the main renal artery in whom systemic anticoagulant therapy was begun 10 days after the vascular accident and in whom the thrombus completely resolved.

Case report

A 63-year-old man was first seen because of bilateral leg pain. He had suffered a myocardial infarction 3 years earlier, followed by recurrent tachyarrhythmias, usually paroxysmal atrial flutter or fibrillation. Angiography showed multiple obstructions in both femoral arteries but patency of the renal arteries (Fig. 1A). His renal function was normal. He underwent bilateral fe-

moral embolectomies and began taking anticoagulants orally.

One year later the patient was transferred to our institution with a 10-day history of epigastric pain, nausea and vomiting. He had been oliguric for several days but was not when transferred.

His temperature was 38.2°C and he had atrial fibrillation, with a ventricular rate of 108 beats/min. His blood pressure was normal, there was no evidence of congestive heart failure, and the peripheral pulses were palpable. The only other abnormality revealed by physical examination was marked tenderness of the right costovertebral angle.

The blood leukocyte count was $13.9 \times 10^9/l$, the blood urea nitrogen level 22 mg/dl (urea level 7.9 mmol/l), the serum creatinine level 2.7 mg/dl (239 $\mu\text{mol/l}$) and the

From the departments of *medicine and †radiology, Montreal General Hospital, McGill University, Montreal

Reprint requests to: Dr. Raymonde F. Gagnon, Division of nephrology, 2nd floor, Livingston Hall, Montreal General Hospital, 1650 Cedar Ave., Montreal, PQ H3G 1A4

creatinine clearance 36 ml/min. The urine contained a trace of protein, and the sediment eight leukocytes and two erythrocytes per high power field; no pathogens were cultured from a specimen. The serum lactic dehydrogenase level was very high, 498 IU/l; the serum levels of alkaline phosphatase and glutamic oxaloacetic transaminase were moderately raised, at 90 and 88 IU/l respectively. The prothrombin time was 12.8 seconds (control time 11.0 seconds). An echocardiogram revealed no abnormalities.

An intravenous pyelogram revealed a nonfunctioning right kidney, and a renal scan showed severe impairment of perfusion of that kidney. A right retrograde pyelogram was normal. Angiography localized the vascular obstruction to the point of origin of the right renal artery from the aorta (Fig. 1B). We tried




FIG. 1A—Good visualization of right renal artery (arrow) before embolic episode.




FIG. 1B—Complete occlusion of same vessel at its aortic origin shortly after thromboembolism.

to catheterize the artery for local infusion of a thrombolytic agent,^{3,6,7} but the clot completely occluded the vessel at its point of origin.

After surgical consultation, and considering the long interval before the embolism was diagnosed, we decided to institute intravenous heparin therapy: 4000 IU was administered every 4 hours for 10 days. Thereafter, oral anticoagulant therapy was given again. The patient's clinical condition improved steadily, with abatement of the fever, resolution of the flank pain and disappearance of the gastrointestinal symptoms. An angiogram obtained 3 weeks later demonstrated recanalization of the renal artery (Figs. 1C and 2); by this time the serum lactic dehydrogenase level had returned to normal, the abnormalities of the urinary sediment had cleared and the serum creatinine level had fallen to 2.1 mg/dl (186 μ mol/l).

Discussion

Numerous reports have indicated that conservative — that is, non-invasive — treatment of renal thromboembolism results in satisfactory recanalization of the obstructed vessel.^{1,2,8-10} In one study that attempted to compare surgical and medical treatment of renal thromboembolism through an analysis of the literature, medical treatment was found to be associated with a lower patient mortality (13%) and a higher rate of kidney salvage (77%).¹¹ In a more recent review of 16 cases of renal artery




FIG. 1C—Recanalization of same artery (arrow) 3 weeks later, following systemic anticoagulant therapy.

embolism managed conservatively (embolectomy was performed in an additional case) it was noted that 12 patients had received systemic anticoagulant therapy; 2 died of other problems, but the 10 who survived, including the 3 survivors with bilateral emboli, either maintained or regained adequate renal function, although 3 (2 with bilateral emboli and 1 with a unilateral embolus) required dialysis for a short time.¹²

Although some of the surgical literature has stressed early and aggressive surgical approaches to renal artery embolism,¹³ other papers have pointed to the often disappointing outcome of surgery and the fact that a return to normal renal function is rare, even after early surgical intervention.¹⁴ There have been several reports of cases in which surgery has reversed anuria and azotemia secondary to massive renal arterial obstruction as late as 6 weeks after the event;¹⁵ however, in at least an equal number of cases renal function has returned to normal after supportive care only.¹⁶

The reasons for the favourable outcome of conservative management are not completely clear, but the presence of collateral blood vessels and the activation of fibrinolytic systems may be contributing factors.

After renal artery embolism, blood usually continues to flow to




FIG. 2—Selective right renal arteriogram, obtained after abdominal aortogram depicted in Fig. 1C, showing mild segmental stenosis in proximal third of vessel (arrow).

the renal parenchyma for two reasons: (a) there may be flow around the embolus, as is often demonstrated by angiography; and (b) in response to the occlusion, capsular, peripelvic and periureteric collateral vessels immediately begin to perfuse the kidney.¹⁷

In vivo fibrinolysis is controlled by an enzymatic process that involves the conversion of an enzyme precursor (plasminogen) into a proteolytic enzyme (plasmin), a reaction mediated by activators found in blood vessels, other body tissues and, in small quantities, the circulating blood.^{18,19} Upon release from arterial endothelial cells, such factors may locally activate plasminogen, which is known to be in contact with the fibrils of fibrin within the clot.²⁰ The activation of these fibrinolytic systems is well illustrated by the recent use of selective renal artery embolization of autologous clot to control renal hemorrhage. Such clots have spontaneously resolved, sometimes within hours after their introduction into the arterial tree.^{21,22} Experiments in animals have confirmed the return of renal perfusion,^{23,24} even after the injection of a massive clot.²⁵

Our case demonstrates that there is a place for conservative management, even in massive renal artery thromboembolism, particularly when underlying medical problems increase the risks of surgery. The most appropriate form of medical therapy, however, remains to be defined. It may well be that spontaneous physiologic revascularization of the arterial tree is the most important factor underlying the success of conservative treatment, with heparin merely preventing further clot formation. The role of systemic or local use of fibrinolytic agents in the treatment of renal artery thromboembolism has not been well studied, but the use of these agents may prove to expedite the normal mechanisms for clot resorption.

We thank Susan Moses, Phyllis Springer and Fay Zeira for their help in preparing this manuscript.

References

- CHEVAL MJ, MEHAN DJ: Nonoperative management of renal artery embolus. *Urology* 1979; 14: 569-572
- HALPERN M: Acute renal artery embolus: a concept of diagnosis and treatment. *J Urol* 1967; 98: 552-561
- MCGONIGLE RJS, TRAFFORD JAP, SHARPSTONE P, TAPSON JS: Survival after bilateral renal artery occlusion. *Br Med J* 1979; 2: 1261-1267
- MILLAN VG, SHER MH, DETERLING RA JR, PACKARD A, MORTON JR, HARRINGTON JT: Transcatheter thromboembolism of acute renal artery occlusion. *Arch Surg* 1978; 113: 1086-1092
- SIEGELMAN SS, CAPLAN LH: Acute segmental renal artery embolism: a distinctive urographic and arteriographic complex. *Radiology* 1967; 88: 509-512
- JONES FE, BLACK PJ, CAMERON JS, CHANTLER C, GILL D, MAISEY MN, OGG CS, SAXTON H: Local infusion of urokinase and heparin into renal arteries in impending renal cortical necrosis. *Br Med J* 1975; 4: 547-549
- TEMES MONTES XL, ALMARAZ JIMÉNEZ MA, LÓRENZO AGUIAR MD, MARTÍNEZ ARA J, SANZ GUJARDO A, MIGUEL ALONSO JL, SAN MARTÍN P, SÁNCHEZ SICILIA L: Renal artery thrombosis occurring in an adult with the idiopathic nephrotic syndrome: results of local treatment with streptokinase. *Clin Nephrol* 1979; 12: 90-92
- BELLMAN S, ODEN B: An unusual case of renal embolism. *Acta Chir Scand* 1960; 120: 276-280
- GAULT MH, STEINER G: Serum and urinary enzyme activity after renal infarction. *Can Med Assoc J* 1965; 93: 1101-1105
- PARKER JM, LORD JD: Renal artery embolism: a case report with return of complete function of the involved kidney following anticoagulant therapy. *J Urol* 1971; 106: 339-341
- MOYER JD, RAO CN, WIDRICH WC, OLSSON CA: Conservative management of renal artery embolus. *J Urol* 1973; 109: 138-143
- LESSMAN RK, JOHNSON SF, COBURN JW, KAUFMAN JJ: Renal artery embolism. Clinical features and long-term follow-up of 17 cases. *Ann Intern Med* 1978; 89: 477-482
- DE LA ROCHA AG, ZORN M, DOWNS AR: Acute renal failure as a consequence of sudden renal artery occlusion. *Can J Surg* 1981; 24: 218-222
- THOMAS TV, FAULCONER HT, LANSING AM: Management of embolic occlusion of renal arteries. *Surgery* 1969; 65: 576-583
- SPANOS PK, TERHORST TR, SAKO Y: Acute prolonged renal arterial infarction. Return of function after thromboendarterectomy. *Am J Surg* 1975; 129: 579-582
- QUANTOCK OP, THATCHER GN: Reversible renal failure with renal artery occlusion. *Br Med J* 1972; 2: 27-28
- LOVE L, BUSH IM: Early demonstration of renal collateral arterial supply. *Am J Roentgen* 1968; 104: 296-301
- EMEIS JJ: The vascular wall and fibrinolysis. *Haemostasis* 1979; 8: 332-339
- ONOYAMA K, TANAKA K: Fibrinolytic activity of the arterial wall. *Thromb Diath Haemorrh* 1969; 21: 1-11
- FLETCHER AP, ALKJAERSIG N, SHERRY S: Fibrinolytic mechanisms and the development of thrombolytic therapy. *Am J Med* 1962; 33: 738-752
- KALISH M, GREENBAUM L, SILBER S, GOLDSTEIN H: Traumatic renal hemorrhage treatment by arterial embolization. *J Urol* 1974; 112: 138-141
- SILBER SJ, CLARK RE: Treatment of massive hemorrhage after renal biopsy with angiographic injection of clot. *N Engl J Med* 1975; 292: 1387-1388
- CARMIGNANI G, BELGRANO E, MARTORANA G, PUPPO P: Clots, Oxvcell, Gelfoam, barium and cyanoacrylates in transcatheter embolization of rat kidney. *Invest Urol* 1978; 16: 9-12
- VLAHOS L, KARATZAS G, PAPAHRALAMBOUS N, PONTIFEX GR: Percutaneous arterial embolization in the kidneys of dogs: a comparative study of eight different materials. *Br J Radiol* 1980; 53: 289-298
- SILBER S: Renal trauma. Treatment by angiographic injection of autologous clot. *Arch Surg* 1975; 110: 206-207

Bactrim™ Roche

Rx Summary

Indications

The following infections when caused by susceptible pathogens:

- upper and lower respiratory tract (particularly chronic bronchitis and including acute and chronic otitis media)
- urinary tract: acute, recurrent and chronic
- genital tract: uncomplicated gonococcal urethritis
- gastrointestinal tract
- skin and soft tissue
- *Pneumocystis carinii* pneumonitis in infants and children.

Not indicated in infections due to *Pseudomonas*, *Mycoplasma* or viruses.

Contraindications

Evidence of marked liver damage or renal impairment where repeated serum assays cannot be carried out; blood dyscrasias; known hypersensitivity to trimethoprim or sulfonamides. During pregnancy, and in newborn or premature infants during first few weeks of life.

Precautions

Benefit should be critically appraised against risk in patients with liver damage, renal damage, urinary obstruction, blood dyscrasias, allergies, or bronchial asthma. Reduce dosage in patients with renal impairment. Do not administer if serum creatinine level is above 2 mg%. Consider possible superinfection with a non-sensitive organism.


Adverse reactions

Most frequent: nausea, vomiting, gastric intolerance, and rash. Less frequent: diarrhea, constipation, flatulence, anorexia, pyrosis, gastritis, gastroenteritis, urticaria, headache, and liver changes (abnormal elevations in alkaline phosphatase and serum transaminase). Occasionally reported: glossitis, oliguria, hematuria, tremor, vertigo, alopecia, and elevated BUN, NPN, and serum creatinine. Hematological changes: primarily, neutropenia and thrombocytopenia, and less frequently, leukopenia, aplastic or hemolytic anemia, purpura, agranulocytosis, and bone marrow depression; occur particularly in the elderly and mostly prove reversible on withdrawal.

Dosage

Children: 6 mg trimethoprim/kg body weight per day, plus 30 mg sulfamethoxazole/kg body weight per day, divided into two equal doses.
Adults and children over 12 years of age:
Standard dosage:
1 'Bactrim' DS 'Roche' tablet or 2 adult tablets, twice daily.
Minimum dosage and dosage for long-term treatment:
½ 'Bactrim' DS 'Roche' tablet or 1 adult tablet, twice daily.
Maximum dosage (overwhelming infections):
1½ 'Bactrim' DS 'Roche' tablets or 3 adult tablets, twice daily.
In acute infections treat for at least 5 days or until patient is asymptomatic for 48 hours; in urinary tract infections, until urine sterile.
Uncomplicated gonorrhoea: 2 adult tablets or 1 'Bactrim' DS 'Roche' tablet four times daily for 2 days.
Pneumocystis carinii pneumonitis: 20 mg/kg/day trimethoprim and 100 mg/kg/day sulfamethoxazole in four divided doses for 14 days.

Supply


Adult tablets: Green, capsule-shaped, biconvex tablet with ROCHE C engraved on one face and BACTRIM and indented score on the other, each containing 80 mg trimethoprim and 400 mg sulfamethoxazole. Bottles of 100 and 500. Unit dose, boxes of 100.
DS tablets: White, capsule-shaped, biconvex tablet with ROCHE engraved on one face and BACTRIM DS and indented score on the other, each containing 160 mg trimethoprim and 800 mg sulfamethoxazole. Bottles of 100 and 250.
Suspension: Cherry flavoured, 40 mg trimethoprim and 200 mg sulfamethoxazole per 5 ml. Bottles of 100 and 400 ml.
Pediatric tablets: White, cylindrical biplane tablet with  engraved on one face, single scored on the other with C above and below score line, each containing 20 mg trimethoprim and 100 mg sulfamethoxazole. Bottles of 100.

Product monograph available on request.

TM: Trade Mark of Hoffmann-La Roche Limited
®Reg. Trade Mark

- Goodman and Gilman, The Pharmacological Basis of Therapeutics, 6th ed., Collier MacMillan Canada Ltd., Toronto 1980, 1116.
- Sanford, J.P., Guide to Antimicrobial Therapy 1979, J.P. Sanford, M.D.

'Bactrim' 'Roche' is listed in provincial formularies.

 Hoffmann-La Roche Limited
Vaudreuil, Québec J7V 6B3

Original Research in Medicine

